The DOI matches its Crossref record; 266 of the 266 references it cites were found in a registry or an index.
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Open accessAbstract
SUMMARY: The global incidence of drug-resistant Gram-negative bacillary infections has been increasing, and there is a dire need to develop novel strategies to overcome this problem. Intrinsic resistance in Gram-negative bacteria, such as their protective outer membrane and constitutively overexpressed efflux pumps, is a major survival weapon that renders them refractory to current antibiotics. Several potential avenues to overcome this problem have been at the heart of antibiotic drug discovery in the past few decades. We review some of these strategies, with emphasis on antibiotic hybrids either as stand-alone antibacterial agents or as adjuvants that potentiate a primary antibiotic in Gram-negative bacteria. Antibiotic hybrid is defined in this review as a synthetic construct of two or more pharmacophores belonging to an established agent known to elicit a desired antimicrobial effect. The concepts, advances, and challenges of antibiotic hybrids are elaborated in this article. Moreover, we discuss several antibiotic hybrids that were or are in clinical evaluation. Mechanistic insights into how tobramycin-based antibiotic hybrids are able to potentiate legacy antibiotics in multidrug-resistant Gram-negative bacilli are also highlighted. Antibiotic hybrids indeed have a promising future as a therapeutic strategy to overcome drug resistance in Gram-negative pathogens and/or expand the usefulness of our current antibiotic arsenal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–266 of 266
Cephalosporin 3'-quinolone esters with a dual mode of action
Albrecht, H. A., Beskid, G., Chan, K. K., Christenson, J. G., Cleeland, R., Deitcher, K. H., Georgopapadakou, N. H., Keith, D. D., & Pruess, D. L. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00163a013 · Cited by 72
Flanagan, M. E., Brickner, S. J., Lall, M. S., Casavant, J. M., Deschenes, L. A., Finegan, S. M., George, D. M., Granskog, K., Hardink, J. R., Huband, M. D., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200012f · Cited by 72
Zhang, L., Chang, J.-J., Zhang, S., Damu, G. L. V., Geng, R., & Zhou, C. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.007 · Cited by 69
Human cathelicidin LL ‐37 and its derivative IG ‐19 regulate interleukin‐32‐induced inflammation
Choi, K.-Y. G., Napper, S., & Mookherjee, N. (2014) · Immunology · doi:10.1111/imm.12291 · Cited by 68
Development of Potent Inhibitors of Pyocyanin Production inPseudomonas aeruginosa
Miller, L. C., O’Loughlin, C. T., Zhang, Z., Siryaporn, A., Silpe, J. E., Bassler, B. L., & Semmelhack, M. F. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5015082 · Cited by 66
The arsenal of pathogens and antivirulence therapeutic strategies for disarming them
Hadjifrangiskou, M., & Brannon, J. R. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s98939 · Cited by 66
Hybrid antibiotics – clinical progress and novel designs
Parkes, A. L., & Yule, I. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1187597 · Cited by 63
Vilà, J., & Martínez, J. L. (2008) · Current Drug Targets · doi:10.2174/138945008785747806 · Cited by 62
A New Cephalosporin with a Dual Mode of Action
O'Callaghan, C. H., SYKES, R. B., & Staniforth, S. E. (1976) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.10.2.245 · Cited by 62
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L. R., Morris, T. W., Roche, E. D., Yan, D., & Lynch, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-07 · Cited by 62
Karlowsky, J. A., Hoban, D. J., Hackel, M., Lob, S. H., & Sahm, D. F. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.03.006 · Cited by 62
Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level
Cinquin, B. P., Maigre, L., Pinet, E., Chevalier, J., Stavenger, R. A., Mills, S. D., Réfrégiers, M., & Pagès, J. (2015) · Scientific Reports · doi:10.1038/srep17968 · Cited by 60
Simonetti, O., Cirioni, O., Cacciatore, I., Baldassarre, L., Orlando, F., Pierpaoli, E., Lucarini, G., Orsetti, E., Provinciali, M., Fornasari, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151956 · Cited by 59
Herrmann, M., Schneck, E., Gutsmann, T., Brandenburg, K., & Tanaka, M. (2015) · Soft Matter · doi:10.1039/c5sm01002k · Cited by 58
Baldoni, D., Gutierrez, M. M., Timmer, W., & Dingemanse, J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt401 · Cited by 58
Amphiphilic Tobramycins with Immunomodulatory Properties
Guchhait, G., Altieri, A., Gorityala, B. K., Yang, X., Findlay, B., Zhanel, G. G., Mookherjee, N., & Schweizer, F. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500598 · Cited by 57
Self-citationSousa, J., Alves, G., Fortuna, A. C., & Falcão, A. C. (2014) · Current Drug Safety · doi:10.2174/1574886308666140106154754 · Cited by 57
Lau, C. H., Hughes, D., & Poole, K. (2014) · mBio · doi:10.1128/mbio.01068-14 · Cited by 57
Partitioning of hydrophobic probes into lipopolysaccharide bilayers
Vaara, M., Plachy, W. Z., & Nikaido, H. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90218-d · Cited by 56
Wang, X., Wei, W., Wang, P., Tang, Y., Deng, R.-C., Li, B., Zhou, S., Zhang, J., Zhang, L., Xiao, Z., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.018 · Cited by 56
Sautrey, G., Zimmermann, L., Deleu, M., Delbar, A., Machado, L. S., Jeannot, K., Françoise Van Bambeke, A., Buyck, J. M., Décout, J., & Mingeot‐Leclercq, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02536-13 · Cited by 56
On the mechanism of solute uptake in Pseudomonas
Hancock, R. E. W. (2003) · Frontiers in bioscience · doi:10.2741/1075 · Cited by 54
Synthesis of Tridecaptin–Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria
Cochrane, S. A., Li, X., He, S., Yu, M., Wu, M., & Vederas, J. C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01578 · Cited by 54
Are the physicochemical properties of antibacterial compounds really different from other drugs?
Ebejer, J.-P., Charlton, M. H., & Finn, P. W. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0143-5 · Cited by 54
Negatively Charged Lipids as a Potential Target for New Amphiphilic Aminoglycoside Antibiotics
Sautrey, G., Khoury, M. E., dos Santos, A. G., Zimmermann, L., Deleu, M., Lins, L., Décout, J., & Mingeot‐Leclercq, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665364 · Cited by 53
A Multivalent Approach to Drug Discovery for Novel Antibiotics
Long, D. D., Aggen, J. B., CHRISTENSEN, B. G., Judice, J. K., Hegde, S. S., Kaniga, K., Krause, K. M., Linsell, M. S., Moran, E. J., & Pace, J. (2008) · The Journal of Antibiotics · doi:10.1038/ja.2008.79 · Cited by 52
Design of dual action antibiotics as an approach to search for new promising drugs
Tevyashova, A. N., Olsufyeva, E. N., & PREOBRAZHENSKAYA, M. N. (2014) · Russian Chemical Reviews · doi:10.1070/rcr4448 · Cited by 52
Total Synthesis and Structural Reassignment of Aspergillomarasmine A
Liao, D., Yang, S., Wang, J., Zhang, J., Hong, B., Wu, F., & Lei, X. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201509960 · Cited by 51
Speculative strategies for new antibacterials: all roads should not lead to Rome
Shapiro, S. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.27 · Cited by 49
Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia
Cigana, C., Bernardini, F., Facchini, M., Alcalá-Franco, B., Riva, C., Fino, I. D., Rossi, A., Ranucci, S., Misson, P., Chevalier, É., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00390-16 · Cited by 49
Jones, R. N., Barry, A. L., & Thornsberry, C. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.6.944 · Cited by 47
Oh, K., Nam, K., Ahn, H., Shin, J., Kim, S., & Mar, W. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.113 · Cited by 46
Mode of action of the dual-action cephalosporin Ro 23-9424
Georgopapadakou, N. H., Bertasso, A., Chan, K. K., et al. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.7.1067 · Cited by 46
Using Engineered Bacteria to Characterize Infection Dynamics and Antibiotic Effects In Vivo
Certain, L., Way, J. C., Pezone, M. J., & Collins, J. J. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.08.001 · Cited by 46
Combination therapy for Gram-negative bacteria: what is the evidence?
Kmeid, J., Youssef, M., Kanafani, Z. A., & Kanj, S. S. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.846215 · Cited by 45
Alasil, S. M., Rahmat, O., Ismail, S. B., & Yusof, M. Y. M. (2015) · International Journal of Bacteriology · doi:10.1155/2015/671562 · Cited by 44
Li, Q., Lee, J. Y., Castillo, R. S., Hixon, M. S., Pujol, C. J., Doppalapudi, V. R., Shepard, H. M., Wahl, G. M., Lobl, T. J., & Chan, M. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1262-1268.2002 · Cited by 44
Berkov‐Zrihen, Y., Herzog, I. M., Benhamou, R. I., Feldman, M., Steinbuch, K. B., Shaul, P., Lerer, S., Eldar, A., & Fridman, M. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201406404 · Cited by 43
Mobashery, S., Lerner, S. A., & Johnston, M. (1986) · Journal of the American Chemical Society · doi:10.1021/ja00267a045 · Cited by 40
Rotem, S., Radzishevsky, I. S., & Mor, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-06 · Cited by 40
Kucharska, I., Liang, B., Ursini, N., & Tamm, L. K. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00630 · Cited by 39
Gziut, M., MacGregor, H., NEVELL, T. G., Mason, T., Laight, D. W., & Shute, J. K. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12018 · Cited by 37
Molecular mechanisms involved in the transport of antibiotics into bacteria
Chopra, I. (1988) · Parasitology · doi:10.1017/s0031182000085966 · Cited by 37
Antimicrobial effects of novel siderophores linked to β-lactam antibiotics
Kline, T. B., Fromhold, M. G., McKennon, T. E., Cai, S., Treiberg, J., Ihle, N., Sherman, D. R., Schwan, W. R., Hickey, M. J., Warrener, P., et al. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00261-8 · Cited by 37
Development of Antivirulence Compounds: A Biochemical Review
Zambelloni, R., Márquez, R., & Roe, A. J. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12430 · Cited by 36
Boucher, H. W., Bakken, J., & Murray, B. E. (2016) · Annals of Internal Medicine · doi:10.7326/m16-2079 · Cited by 34
Tomaras, A. P., Crandon, J. L., McPherson, C. J., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04172-14 · Cited by 32
Mechanism of Action of NB2001 and NB2030, Novel Antibacterial Agents Activated by β-Lactamases
Stone, G. W., Zhang, Q., Castillo, R. S., Doppalapudi, V. R., Bueno, A. R., Lee, J. Y., Li, Q., Sergeeva, M. V., Khambatta, G., & Georgopapadakou, N. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.477-483.2004 · Cited by 32
Multidrug-Resistant Gram-Negative Bacilli
Adler, A., Friedman, N. D., & Marchaim, D. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.08.001 · Cited by 32
Cochrane, S. A., & Vederas, J. C. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.08.008 · Cited by 31
Cadazolid for the treatment of Clostridium difficile
Endres, B. T., Bassères, E., Alam, M. J., & Garey, K. W. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1304538 · Cited by 31
Takrouri, K., Cooper, H. D., Spaulding, A. E., Zucchi, P., Koleva, B. N., Cleary, D. C., Tear, W. F., Beuning, P. J., Hirsch, E. B., & Aggen, J. B. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00003 · Cited by 30
Kowata, H., Tochigi, S., Kusano, T., & Kojima, S. (2016) · The Journal of Antibiotics · doi:10.1038/ja.2016.50 · Cited by 29
The membranes of Gram-negative bacteria: progress in molecular modelling and simulation
Khalid, S., Berglund, N. A., Holdbrook, D. A., Leung, Y. M., & Parkin, J. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140262 · Cited by 29
Marynka, K., Rotem, S., Portnaya, I., Cogan, U., & Mor, A. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.009 · Cited by 28
Livermore, D. M., Mushtaq, S., Warner, M., & Woodford, N. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt455 · Cited by 28
A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway
Wang, K. K., Stone, L. K., Lieberman, T. D., Shavit, M., Baasov, T., & Kishony, R. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msv243 · Cited by 27
The Management of Acute Uncomplicated Cystitis in Adult Women by Family Physicians in Canada
McIsaac, W. J., Prakash, P., & Ross, S. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/404939 · Cited by 23
Domalaon, R., Yang, X., O’Neil, J. D., Zhanel, G. G., Mookherjee, N., & Schweizer, F. (2014) · Amino Acids · doi:10.1007/s00726-014-1806-z · Cited by 23
Self-citationLyu, Y., Domalaon, R., Yang, X., & Schweizer, F. (2017) · Peptide Science · doi:10.1002/bip.23091 · Cited by 22
Self-citationControlling bacterial infections by inhibiting proton-dependent processes
Kaneti, G., Meir, O., & Mor, A. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.10.022 · Cited by 21
Mobashery, S., & Johnston, M. (1987) · Biochemistry · doi:10.1021/bi00392a045 · Cited by 19
Heidari‐Torkabadi, H., Che, T., Lombardo, M. N., Wright, D. L., Anderson, A. C., & CAREY, P. R. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00202 · Cited by 15
Straubinger, M., Blenk, H., Naber, K. G., & Wagenlehner, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02425-15 · Cited by 13
Williams, S. C. P. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413117111 · Cited by 9
Cited by
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
The global preclinical antibacterial pipeline
Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0288-0 · Cited by 738
Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era
Wang, J., Dou, X., Song, J., Lyu, Y., Zhu, X., Xu, L., Li, W., & Shan, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21542 · Cited by 547
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
Self-citationAntibiotic Adjuvants: Make Antibiotics Great Again!
Douafer, H., Andrieu, V., Phanstiel, O., & Brunel, J. M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01781 · Cited by 272
Metadata
- Authors
- Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2018-04
- Volume
- 31
- Issue
- 2
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2792453421
- Cited by
- 285
- References
- 266
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.